(AOF) – CVS Health is expected to break even in pre-market on Wall Street after announcing today the launch of Cordavis, a subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products for the US pharmaceutical market. For its first product, Cordavis has entered into an agreement with Sandoz to commercialize Hyrimoz, a biosimilar of Humira, in the first quarter of 2024 for a list price more than 80% below the current list price of Humira.
“CVS Health has a tradition of providing innovative solutions that lower the cost of medications and ensure patients have access to the medications they need to stay healthy,” said Shawn Guertin, Chief Financial Officer of CVS Health. “Cordavis is a logical next step for us and will help ensure an adequate supply of biosimilars in the United States and support this market, while improving health outcomes and reducing costs for consumers.”
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
